ArticleCureus2025
Exploring the Theoretical Potential of Benzphetamine in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD).
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Benzphetamine HCl (Didrex) is a Schedule III amphetamine indicated for the treatment of obesity. Amphetamine and methylphenidate are CNS stimulants regarded as the most effective treatment for attention-deficit/hyperactivity disorder (ADHD). Currently, both classes comprise the nationwide shortage of stimulants used to treat ADHD. Benzphetamine is a prodrug yielding dextroamphetamine (Zenzedi) and dextromethamphetamine (formerly Desoxyn). Both metabolites hold FDA approval to treat ADHD, suggesting their potential to aid in the shortage. Nonetheless, the lack of data on the compound limits its hypothetical applicability, thus prompting a theoretical review. Prior studies found dextroamphetamine to be more potent than benzphetamine and suggested the behavior of the compounds to differ; despite this, the absence of data in ADHD subjects and the limited data on obese subjects significantly limited our investigation. While benzphetamine appears mechanistically promising, the paucity of literature prevented us from drawing a theoretical claim. This editorial examined the theoretical pharmacological rationale for benzphetamine based on known mechanisms; it does not present new clinical data, efficacy claims, or treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.